Drug Profile
Research programme : bispecific monoclonal antibody - Integral Molecular
Alternative Names: Anti-CD3 x anti-Claudin 6 bispecific monoclonal antibody - Integral Molecular; CLDN6xCD3 bsAb - Integral MolecularLatest Information Update: 11 Dec 2022
Price :
$50
*
At a glance
- Originator Integral Molecular
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Endometrial cancer; Ovarian cancer
Most Recent Events
- 09 Nov 2022 Context Therapeutics announces its intention to select a candidate to support IND-enabling studies for CLDN6xCD3 bispecific monoclonal antibody in December 2022
- 27 Sep 2022 Context Therapeutics plans to submit an IND application for Endometrial and Ovarian cancer in the first quarter of 2024
- 05 Jan 2022 Preclinical trials in Endometrial cancer in USA (Parenteral)